- Condition: Healthy Volunteer
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: tenofovir disoproxil fumarate; Drug: atazanavir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Condition: HIV
Intervention: Drug: 3 drug regimen: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
Sponsors: Fenway Community Health; Kenneth H. Mayer, MD; Bristol-Myers Squibb; Gilead Sciences; Abbott
Recruiting - verified May 2012 - Conditions: HIV; PCP; Toxoplasmosis
Interventions: Drug: Atovaquone 750 mg twice daily; Drug: Atovaquone 1500 mg twice daily
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified October 2011 - Condition: Human Immunodeficiency Virus
Intervention: Drug: Atripla (EFV/TDF/FTC); boosted darunavir & tenofovir/FTC; boosted atazanavir & tenofovir/FTC; raltegravir & tenofovir/FTC
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011 - Conditions: Women's Health; HIV Infection; Genital Diseases, Female
Intervention:
Sponsors: University of Colorado, Denver; University of Colorado, Denver
Recruiting - verified October 2011 - Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Atazanavir
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Institutes of Health (NIH)
Not yet recruiting - verified August 2011 - Condition: HIV Infected
Intervention: Drug: Tenofovir, Emtricitabine, Atazanavir, Ritonavir
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Human Immunodeficiency Virus-1
Interventions: Drug: BMS-663068; Drug: BMS-663068; Drug: BMS-663068; Drug: BMS-663068; Drug: Raltegravir; Drug: Raltegravir; Drug: Tenofovir; Drug: Tenofovir; Drug: Ritonavir; Drug: Atazanavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir DF; Drug: cobicistat and atazanavir or cobicistat and darunavir
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV
Interventions: Drug: Atazanavir Sulphate; Drug: Ritonavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: HIV, Combination Therapy
Interventions: Drug: Atazanavir; Drug: Ritonavir (heat-stable); Drug: Raltegravir; Drug: Tenofovir/Emtricitabine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: ADHD
Intervention:
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Recruiting - verified May 2012 - Condition: Human Immunodeficiency Virus
Interventions: Drug: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV); Drug: tenofovir/emtricitabine (TDF/FTC); Drug: Atazanavir (ATV); Drug: Ritonavir; Procedure: Phlebotomy
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Society of Infectious Diseases Pharmacists; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: HIV Infections
Interventions: Drug: Raltegravir (RAL); Drug: Atazanavir (ATV); Drug: Ritonavir (RTV); Drug: Tenofovir (TDF); Drug: Etravirine (ETV); Drug: Darunavir (DRV); Drug: Maraviroc (MVC); Drug: Lopinavir/ritonavir (LPV/r)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: HIV Infections; Drug Abuse
Interventions: Drug: Disulfiram; Drug: Disulfiram + Efavirenz; Drug: Disulfiram + Atazanavir; Drug: Disulfiram + Ritonavir
Sponsors: University of California, San Francisco; University of California, San Francisco; National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2011 - Conditions: Acquired Immune Deficiency Syndrome; AIDS; Human Immunodeficiency Virus; HIV Infections
Interventions: Drug: Raltegravir; Drug: Atazanavir; Other: Standard treatment regimen
Sponsors: Yale University; Yale University; Bristol-Myers Squibb; Merck
Recruiting - verified February 2012 - Condition: HIV Infections
Intervention: Drug: ARV regimen chosen by treating physician
Sponsors: University of North Carolina, Chapel Hill; Kristine Patterson, MD; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012
 |
Atazanavir Clinical Trials |
